Tag: memorial-sloan-

MSK begins CAR T cell clinical trial for children with relapsed or treatment-resistant ALL

| April 12, 2015 | 0 Comments

Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

Continue Reading

Cancer patients want more info about CT risks

| March 24, 2015 | 0 Comments

By Kathryn Doyle (Reuters Health) – – Some cancer patients would like more information on the health risks of their radiology tests, a new study found. “Before completing this study, I believed I understood what patients may wish to know and how to provide that information to them,” said Dr. Raymond Thornton, the study’s lead author from Memorial Sloan-Kettering Cancer Center in New York City …

Continue Reading

Cancer Genetics Inc to Present New Data on Identification of Genomic Changes That Predict Both Metastasis and Site of …

| February 24, 2015 | 0 Comments

> CGI's genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC)

Continue Reading

Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's …

| January 6, 2015 | 0 Comments

SAN DIEGO, Jan. 6, 2015 /PRNewswire/ —

Continue Reading

Mesothelioma Research Foundation’s Message to the Pharmaceutical Industry

| December 26, 2014 | 0 Comments

Last month, the chair of the board of directors of the Mesothelioma Applied Research Foundation and oncologist at Memorial Sloan Kettering Cancer Center, Lee M. Krug, MD, penned a blog post message to the pharmaceutical industry that recruitment of patients with mesothelioma to large trials is feasible, and encouraging them to pursue drug development in that uncommon disease. (PRWeb December 26 …

Continue Reading

New Clinical Data Supports the Use of FoundationOne® Heme to Enable Informed Treatment Decisions in a Wide Range of …

| December 9, 2014 | 0 Comments

Foundation Medicine, Inc. today announced new data demonstrating that FoundationOne® Heme, developed in collaboration with Memorial Sloan Kettering Cancer Center, provides critical genomic information that can impact prognosis, influence therapeutic strategy and even refine conventional pathologic diagnosis in patients with a wide range of hematologic malignancies.

Continue Reading

Memorial Sloan Kettering Cancer Center Selects CooperKatz & Company as Public Relations Agency of Record

| December 2, 2014 | 0 Comments

Memorial Sloan Kettering Cancer Center , the world’s oldest and largest private cancer center, has retained CooperKatz & Company as its strategic communications partner, f

Continue Reading

Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and …

| September 17, 2014 | 0 Comments

Memorial Sloan Kettering, MD Anderson and Brigham and Women’s Hospital Cited for Exemplary Services (PRWeb September 17, 2014) Read the full story at http://www.prweb.com/releases/2014/09/prweb12173892.htm

Continue Reading

Hartford HealthCare Launches Alliance With Leading NYC Cancer Center

| September 16, 2014 | 0 Comments

HARTFORD — The alliance Hartford HealthCare announced a year ago with Memorial Sloan Kettering to tap into the leading New York cancer center's research and treatment capabilities is moving forward.

Continue Reading

Hartford HealthCare Launches Alliance With Memorial Sloan Kettering Cancer Center

| September 16, 2014 | 0 Comments

The alliance Hartford HealthCare announced a year ago with Memorial Sloan Kettering to tap into the leading New York cancer center's research and treatment capabilities is moving forward.

Continue Reading